Study links symptomatic chlamydia to higher risk of reproductive complications

In a recent prospective cohort study published in The Lancet Regional Health – Europe, researchers from the Netherlands investigated the risks of reproductive complications after asymptomatic and symptomatic infections with Chlamydia trachomatis (chlamydia).

They found that only symptomatic chlamydia infections significantly increased the risk of pelvic inflammatory disease (PID), ectopic pregnancy, and tubal factor infertility, although the incidence of these complications remained low.

Study: Reproductive tract complication risks following Chlamydia trachomatis infections: a long-term prospective cohort study from 2008 to 2022. Image Credit: New Africa/Shutterstock.comStudy: Reproductive tract complication risks following Chlamydia trachomatis infections: a long-term prospective cohort study from 2008 to 2022. Image Credit: New Africa/Shutterstock.com

Background

Chlamydia trachomatis is the most common bacterial sexually transmitted infection globally. Its widespread testing aims at reducing complications like PID, which may lead to tubal infertility and ectopic pregnancy. While individual-level screening reduces PID risk, achieving population-level impact has been challenging, especially for asymptomatic cases, which are common.

Previous randomized controlled trials have indicated increased risks for reproductive complications post-chlamydia infection, but data misclassification and inconsistent diagnostic methods have limited their accuracy.

Prospective studies with updated chlamydia status and comprehensive fertility outcomes could offer a more accurate assessment of chlamydia's impact on female fertility.

Therefore, researchers in the present study assessed the long-term risks of chlamydia-associated complications (PID, tubal factor infertility, and ectopic pregnancy) and their impact on pregnancy, comparing outcomes for asymptomatic and symptomatic infections to potentially guide chlamydia policy and treatment.

About the study

This study involved a long-term prospective cohort of 5704 reproductive-age women, of mean age 35.3 years, from the Netherlands Chlamydia Cohort Study. About 64.7% of the participants had been pregnant at least once. They were recruited from a prior chlamydia screening study and were followed from 2008 to 2022.

Data on chlamydia infections, pregnancies, and reproductive complications were collected through questionnaires and merged with previous screening data.

Chlamydia exposure was classified based on polymerase chain reaction (PCR) test results, self-reported infections, and serological tests for the presence of chlamydia antibodies.

The study aimed to assess risks of PID, ectopic pregnancy, tubal factor infertility, and time to pregnancy in chlamydia-positive (n = 2103) vs. chlamydia-negative women (n = 3691) over time.

Statistical analysis involved the use of Student's t-test, Mann–Whitney U-test, chi-square tests, Kaplan–Meier curves, Cox proportional hazards regression model, and confounder assessment, followed by stratified and sensitivity analysis.

Results and discussion

Of the total participants, 36.2% completed all four study rounds, while others contributed to fewer rounds. The mean age at sexual debut was found to be 16.9 years, with an average exposure time of 18.3 years.

Chlamydia-positive women were found to have a higher body mass index, a younger age at sexual debut, more lifetime sexual partners, and increased gonorrhea positivity compared to chlamydia-negative women.

About 4.1% of the participants had at least one episode of PID, 1.6% of them reported at least one ectopic pregnancy, and 1% of them were diagnosed with tubal factor infertility.

Chlamydia-positive women were found to have significantly higher rates of PID at 3.80 per 1000 person-years, compared to 1.80 per 1,000 person-years in chlamydia-negative women. For symptomatic chlamydia, the incidence was even higher at 5.82 per 1000 person-years.

Multivariable analyses showed that chlamydia-positivity was associated with increased risks of PID (adjusted hazard ratio [aHR] 1.62), ectopic pregnancy (aHR 1.84), and tubal factor infertility (aHR 2.75).

Interestingly, while symptomatic chlamydia infections were linked to a higher risk of adverse reproductive outcomes, asymptomatic infections were not found to show the same association.

Pregnancy rates were found to be higher among chlamydia-positive women (67.2 per 1000 person-years) compared to chlamydia-negatives (41.9 per 1000 person-years) during the first exposure interval. However, there were lower chances of planned pregnancies among chlamydia-positive women in the younger age groups (16–25 years and 26–33 years).

No significant difference was observed in the older age groups (34–42 years). While overall pregnancy chances were not decreased after chlamydia infection, the duration required to conceive was longer for those with a history of chlamydia.

This is the first prospective study to provide a long-term, large-scale, cohort-based analysis of chlamydia's reproductive risks. However, the study is limited by its potential misclassification of lifetime chlamydia status, reliance on self-reported outcomes, possible diagnostic and selection biases, and unmeasured residual confounding.

Conclusion

In conclusion, the study reveals the long-term reproductive health risks associated with chlamydia infections, highlighting that symptomatic chlamydia infections pose a greater risk for complications like PID, ectopic pregnancy, and tubal factor infertility.

Despite the low incidence of reproductive risks found in the study, the researchers emphasize the importance of primary prevention, early detection, and timely treatment of chlamydia, especially in young women.

In the future, tailored screening and public health strategies for chlamydia would be required, that also consider social and healthcare access disparities to improve health outcomes in women of reproductive age.

Journal reference:
Dr. Sushama R. Chaphalkar

Written by

Dr. Sushama R. Chaphalkar

Dr. Sushama R. Chaphalkar is a senior researcher and academician based in Pune, India. She holds a PhD in Microbiology and comes with vast experience in research and education in Biotechnology. In her illustrious career spanning three decades and a half, she held prominent leadership positions in academia and industry. As the Founder-Director of a renowned Biotechnology institute, she worked extensively on high-end research projects of industrial significance, fostering a stronger bond between industry and academia.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chaphalkar, Sushama R.. (2024, August 21). Study links symptomatic chlamydia to higher risk of reproductive complications. News-Medical. Retrieved on October 06, 2024 from https://www.news-medical.net/news/20240821/Study-links-symptomatic-chlamydia-to-higher-risk-of-reproductive-complications.aspx.

  • MLA

    Chaphalkar, Sushama R.. "Study links symptomatic chlamydia to higher risk of reproductive complications". News-Medical. 06 October 2024. <https://www.news-medical.net/news/20240821/Study-links-symptomatic-chlamydia-to-higher-risk-of-reproductive-complications.aspx>.

  • Chicago

    Chaphalkar, Sushama R.. "Study links symptomatic chlamydia to higher risk of reproductive complications". News-Medical. https://www.news-medical.net/news/20240821/Study-links-symptomatic-chlamydia-to-higher-risk-of-reproductive-complications.aspx. (accessed October 06, 2024).

  • Harvard

    Chaphalkar, Sushama R.. 2024. Study links symptomatic chlamydia to higher risk of reproductive complications. News-Medical, viewed 06 October 2024, https://www.news-medical.net/news/20240821/Study-links-symptomatic-chlamydia-to-higher-risk-of-reproductive-complications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin B12 boosts testosterone levels in men with infertility